We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

22 hedge funds and large institutions have $3.82M invested in Bellerophon Therapeutics, Inc. in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0% more funds holding

Funds holding: 22 → 22 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

20% less capital invested

Capital invested by funds: $4.81M → $3.82M (-$986K)

Holders
22
Holders Change
–
Holders Change %
0%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$246K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$96.6K
3
Millennium Management
Millennium Management
New York
+$80.1K
4
TI
Telemetry Investments
New York
+$57.4K
5
TSS
Two Sigma Securities
New York
+$37.1K

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$166K
2
ACM
ACT Capital Management
Pennsylvania
-$102K
3
Renaissance Technologies
Renaissance Technologies
New York
-$75.7K
4
HF
HRT Financial
New York
-$48K
5
Rockefeller Capital Management
Rockefeller Capital Management
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.15M +$96.6K +29,098 +9%
Wells Fargo
2
Wells Fargo
California
$620K -$166K -50,000 -20%
Renaissance Technologies
3
Renaissance Technologies
New York
$555K -$75.7K -22,807 -11%
BlackRock
4
BlackRock
New York
$378K +$3.49K +1,050 +0.9%
TI
5
Telemetry Investments
New York
$319K +$57.4K +17,281 +20%
Jane Street
6
Jane Street
New York
$230K +$246K +74,060 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$180K -$83 -25 -0%
Northern Trust
8
Northern Trust
Illinois
$113K -$807 -243 -0.7%
Millennium Management
9
Millennium Management
New York
$75K +$80.1K +24,134 New
State Street
10
State Street
Massachusetts
$66K – – –
Tudor Investment Corp
11
Tudor Investment Corp
Connecticut
$62K – – –
TSS
12
Two Sigma Securities
New York
$35K +$37.1K +11,161 New
Morgan Stanley
13
Morgan Stanley
New York
$17K +$12.2K +3,664 +201%
UBS Group
14
UBS Group
Switzerland
$7K +$3.48K +1,049 +90%
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$7K +$7.49K +2,255 +1,296%
US Bancorp
16
US Bancorp
Minnesota
$4K – – –
Osaic Holdings
17
Osaic Holdings
Arizona
$3K – – –
Northwestern Mutual Wealth Management
18
Northwestern Mutual Wealth Management
Wisconsin
$2K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$2K +$2.32K +698 New
Federated Hermes
20
Federated Hermes
Pennsylvania
$1K +$545 +164 New
ACM
21
ACT Capital Management
Pennsylvania
– -$102K -25,000 Closed
HF
22
HRT Financial
New York
– -$48K -11,879 Closed
Rockefeller Capital Management
23
Rockefeller Capital Management
New York
– -$22K -5,500 Closed
PFA
24
Professional Financial Advisors
Nebraska
– -$2K -500 Closed
HI
25
Harbour Investments
Wisconsin
– -$1K -241 Closed
1
2

BLPH Hedge Fund Activity: Q4 2021 in Review

22 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2021, worth a combined $3.82M — down 20% from $4.81M a quarter earlier.

Fund positioning in BLPH was balanced in Q4 2021: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $246K. The largest seller was Wells Fargo, cutting an estimated $166K.

  • 22 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $3.82M of Bellerophon Therapeutics, Inc. stock for Q4 2021, down 20% quarter-over-quarter.
  • 5 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2021 and 5 closed out, a net change of 0 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q4 2021 was Jane Street, an estimated $246K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q4 2021 was Wells Fargo, an estimated $166K sold.

Based on aggregated 13F filings for Q4 2021.